Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study

[1]  R. Tollenaar,et al.  Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women , 2017, Journal of the National Cancer Institute.

[2]  D. Eccles,et al.  Local Recurrence and Breast Oncological Surgery in Young Women With Breast Cancer , 2016, Annals of surgery.

[3]  L. Pusztai,et al.  Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis , 2016, PLoS medicine.

[4]  O. Olopade,et al.  Effect of BRCA germline mutations on breast cancer prognosis , 2016, Medicine.

[5]  Jinbo Chen,et al.  RE: Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction. , 2015, Journal of the National Cancer Institute.

[6]  R. Tollenaar,et al.  Worse Breast Cancer Prognosis of BRCA1/BRCA2 Mutation Carriers: What's the Evidence? A Systematic Review with Meta-Analysis , 2015, PloS one.

[7]  D. Altman,et al.  Obesity and the outcome of young breast cancer patients in the UK: the POSH study. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  A. Whittemore,et al.  Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer , 2014, Clinical Cancer Research.

[9]  D G Altman,et al.  Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study , 2013, British Journal of Cancer.

[10]  J. Lubiński,et al.  Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Altman,et al.  Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study. , 2013, Journal of the National Cancer Institute.

[12]  A. Tutt,et al.  Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence? , 2012, Breast Cancer Research.

[13]  Gord Glendon,et al.  Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer , 2012 .

[14]  John L Hopper,et al.  Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Päivi Heikkilä,et al.  Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[16]  J. Lubiński,et al.  Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Paul C. Lambert,et al.  Further Development of Flexible Parametric Models for Survival Analysis , 2009 .

[18]  P. Goodwin,et al.  Prognosis of BRCA-associated breast cancer: a summary of evidence , 2009, Breast Cancer Research and Treatment.

[19]  J. Marks,et al.  Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2008, Journal of clinical epidemiology.

[21]  H A Risch,et al.  The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions , 2008, British Journal of Cancer.

[22]  A. Howell,et al.  Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status , 2007, International journal of cancer.

[23]  D. Altman,et al.  PROSPECTIVE STUDY OF OUTCOMES IN SPORADIC VERSUS HEREDITARY BREAST CANCER , 2004 .

[24]  Ofra Barnett-Griness,et al.  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. , 2007, The New England journal of medicine.

[25]  Giske Ursin,et al.  Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. , 2006, Cancer research.

[26]  J. Satagopan,et al.  A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment , 2003, Breast Cancer Research.

[27]  A. Vincent-Salomon,et al.  Familial invasive breast cancers: worse outcome related to BRCA1 mutations. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Anglian Breast Cancer Study Group.  Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases , 2000 .

[29]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[30]  J. Klijn,et al.  Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 , 1998, The Lancet.